Abstract
Antipsychotic drugs (APD) are widely prescribed for the treatment of schizophrenia. The APD are differentiated into typical and atypical based on the lower incidence of extra-pyramidal side-effects associated with the newer atypical APD. It was suggested that atypicality may arise from an interaction with the 5-hydroxytryptamine (5-HT)2 receptor and specifically on the 5-HT2:dopamine D2 affinity ratio. It is now realised that multiple subtypes of these receptors exist and that in addition, atypical APD interact with many monoamine receptors. The aim of the present study was to characterise the interaction of APD with a variety of monoamine receptors in terms of both affinity and efficacy. The data produced has highlighted that the atypical profile of APD such as olanzapine and clozapine may reflect antagonism of the 5-HT2A and 5-HT2C receptors, whilst that of, ziprasidone and quetiapine may reflect partial agonist activity at the 5-HT1A receptor, and that of aripiprazole may reflect partial agonist activity at the 5-HT1A receptor as well as is its claimed partial agonist activity at the dopamine D2 receptor.
Keywords: Antipsychotic, pharmacology, monoamine receptors, function, binding
CNS & Neurological Disorders - Drug Targets
Title: Pharmacological Profile of Antipsychotics at Monoamine Receptors: Atypicality Beyond 5-HT2A Receptor Blockade
Volume: 5 Issue: 4
Author(s): Martyn D. Wood, Claire Scott, Kirsten Clarke, Katherine J. Cato, Nisha Patel, Jennie Heath, Angela Worby, Laurie Gordon, Lorraine Campbell, Graham Riley, Ceri H. Davies, Andrew Gribble and Declan N.C. Jones
Affiliation:
Keywords: Antipsychotic, pharmacology, monoamine receptors, function, binding
Abstract: Antipsychotic drugs (APD) are widely prescribed for the treatment of schizophrenia. The APD are differentiated into typical and atypical based on the lower incidence of extra-pyramidal side-effects associated with the newer atypical APD. It was suggested that atypicality may arise from an interaction with the 5-hydroxytryptamine (5-HT)2 receptor and specifically on the 5-HT2:dopamine D2 affinity ratio. It is now realised that multiple subtypes of these receptors exist and that in addition, atypical APD interact with many monoamine receptors. The aim of the present study was to characterise the interaction of APD with a variety of monoamine receptors in terms of both affinity and efficacy. The data produced has highlighted that the atypical profile of APD such as olanzapine and clozapine may reflect antagonism of the 5-HT2A and 5-HT2C receptors, whilst that of, ziprasidone and quetiapine may reflect partial agonist activity at the 5-HT1A receptor, and that of aripiprazole may reflect partial agonist activity at the 5-HT1A receptor as well as is its claimed partial agonist activity at the dopamine D2 receptor.
Export Options
About this article
Cite this article as:
Wood D. Martyn, Scott Claire, Clarke Kirsten, Cato J. Katherine, Patel Nisha, Heath Jennie, Worby Angela, Gordon Laurie, Campbell Lorraine, Riley Graham, Davies H. Ceri, Gribble Andrew and Jones N.C. Declan, Pharmacological Profile of Antipsychotics at Monoamine Receptors: Atypicality Beyond 5-HT2A Receptor Blockade, CNS & Neurological Disorders - Drug Targets 2006; 5 (4) . https://dx.doi.org/10.2174/187152706777950693
DOI https://dx.doi.org/10.2174/187152706777950693 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Value of Adeno Associated Virus as a Gene Therapy Vector for Parkinson's Disease – A Focused Review
Current Gene Therapy Memantine and Kynurenic Acid: Current Neuropharmacological Aspects
Current Neuropharmacology Polyamine Modulation of NMDARs as a Mechanism to Reduce Effects of Alcohol Dependence
Recent Patents on CNS Drug Discovery (Discontinued) Recent Developments in the Discovery of Novel Antipsychotic Agents Modualating Dopamine and Serotonin Receptors
Current Drug Targets Chemical Biology of mGlu4 Receptor Activation: Dogmas, Challenges, Strategies and Opportunities
Current Topics in Medicinal Chemistry The Importance of Melatonin and Mitochondria Interaction in Mood Disorders and Schizophrenia: A Current Assessment
Current Medicinal Chemistry Effects of Alcohol in the Lung
Current Respiratory Medicine Reviews Nitric Oxide and Dietary Factors: Part IV Traditional Japanese Food (Soy Products, Fish and Tea)
Vascular Disease Prevention (Discontinued) Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA)
Current Neuropharmacology A Case of Akathisia induced by Escitalopram: Case Report & Review of Literature
Current Drug Safety In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson’s Disease
Current Neuropharmacology Natural Monophenols as Therapeutics, Antioxidants and Toxins; Electron Transfer, Radicals and Oxidative Stress
The Natural Products Journal A Review of Voltammetric Methods for Determination of Dopamine Agonists
Current Analytical Chemistry Treatment of Parkinson’s Disease by MAO-B Inhibitors, New Therapies and Future Challenges - A Mini-Review
Combinatorial Chemistry & High Throughput Screening Quetiapine to Treat Agitation in Dementia: A Randomized, Double-Blind,Placebo-Controlled Study
Current Alzheimer Research Mutations in PRKN and SNCA Genes Important for the Progress of Parkinson’s Disease
Current Genomics Nicotinic Receptors and the Treatment of Attentional and Cognitive Deficits in Neuropsychiatric Disorders: Focus on the α7 Nicotinic Acetylcholine Receptor as a Promising Drug Target for Schizophrenia
Central Nervous System Agents in Medicinal Chemistry Oxidative Stress and Antioxidant Potential of One Hundred Medicinal Plants
Current Topics in Medicinal Chemistry Green Tea, A Medicinal Food with Promising Neurological Benefits
Current Neuropharmacology Drug Therapy for Patients with Eating Disorders
Current Drug Targets - CNS & Neurological Disorders